MDMA-assisted PTSD

therapyIgnacy Stefanczyk

UNIWERSYTET KARDYNAŁA STEFANA WYSZYNSKIEGO

W WARSZAWIE

WYDZIAŁ BIOLOGII I NAUK O ŚRODOWISKU

Plan prezentacji

Charakterystyka substancji

Właściwa terapia stresu pourazowego

Dyskusja wyników

Podsumowanie

Literatura

Charakterystyka substancji

->Ecstasy - chemical structure

->MDMA - psychological profile

->Entactogens, a general outline

MDMA structure

Terapia własciwa

->The studied cases

->Case explanation

->Subject criteria

->Therapy outline

MAPS video concerning the therapeutic process

->MAPS is an institute for mental

health supported by psychodelic use.

Dyskusja wynikow

->Subject 4 met criteria for tachycardia

->Double-blind test importance

->The placebo effect

->Long-term effects

Podsumowanie

In conclusion, low doses of MDMA administered as an adjunct to psychotherapy were found to be safe for the six subjects with chronic

PTSD treated in this clinical trial and there were promising signs of efficacy and reduced PTSD symptomatology. Further studies with a

larger sample size and with the administration of higher doses of MDMA are clearly needed in order to clarify both the safety and the

efficacy of MDMA-assisted psychotherapy in patient populations.

MAPS homepage

Literatura

1.M. Mithofer, MAPS bulletin, 2006, availble at:LINK

2. Doblin, R.E. 2002. A clinical plan for MDMA (Ecstasy) in the treatment of posttraumatic stress disorder (PTSD): Partnering with the

FDA. Journal of Psychoactive Drugs 34 (2): 185-94. link

3. Poch, J. & Ávila, A. 1998. Investigación en Psicoterapia. Barcelona: Paidós.

4. Jansen, KLR 1999. Drug and Alcohol Dependence, Elsevier Volume 53, Issue 2,, Pages 121–124, avaialble at: link

5. Greer, G. & Tolbert, R. 1990. The therapeutic use of MDMA. In: S.J. Peroutka (Ed.) Ecstasy: The Clinical, Pharmacological and

Neurotoxicological Effects of the Drug MDMA. Boston: Kluver Academic Publishers. link